1
|
Xia Q, Takeda K, Yamaguchi Y, Zhang J. A generalized Bayesian optimal interval design for dose optimization in immunotherapy. Pharm Stat 2024; 23:480-494. [PMID: 38295856 DOI: 10.1002/pst.2369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 01/12/2024] [Accepted: 01/21/2024] [Indexed: 07/13/2024]
Abstract
For novel immuno-oncology therapies, the primary purpose of a dose-finding trial is to identify an optimal dose (OD), defined as the tolerable dose having adequate efficacy and immune response under the unpredictable dose-outcome (toxicity, efficacy, and immune response) relationships. In addition, the multiple low or moderate-grade toxicities rather than dose-limiting toxicities (DLTs) and multiple levels of efficacy should be evaluated differently in dose-finding to determine true OD for developing novel immuno-oncology therapies. We proposed a generalized Bayesian optimal interval design for immunotherapy, simultaneously considering efficacy and toxicity grades and immune response outcomes. The proposed design, named gBOIN-ETI design, is model-assisted and easy to implement to develop immunotherapy efficiently. The operating characteristics of the gBOIN-ETI are compared with other dose-finding trial designs in oncology by simulation across various realistic settings. Our simulations show that the gBOIN-ETI design could outperform the other available approaches in terms of both the percentage of correct OD selection and the average number of patients allocated to the OD across various realistic trial settings.
Collapse
Affiliation(s)
- Qing Xia
- Global Biostatistics Science, Amgen Inc, Camarillo, California, USA
| | - Kentaro Takeda
- Data Science, Astellas Pharma Global Development, Inc, Northbrook, Illinois, USA
| | - Yusuke Yamaguchi
- Data Science, Astellas Pharma Global Development, Inc, Northbrook, Illinois, USA
| | - Jun Zhang
- Data Science, Astellas Pharma China, Beijing, China
| |
Collapse
|
2
|
Qiu Y, Zhao Y, Liu H, Cao S, Zhang C, Zang Y. Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose. Contemp Clin Trials 2023; 127:107139. [PMID: 36870476 PMCID: PMC10065963 DOI: 10.1016/j.cct.2023.107139] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2022] [Revised: 01/24/2023] [Accepted: 02/25/2023] [Indexed: 03/06/2023]
Abstract
Conventional phase I/II clinical trial designs often use complicated parametric models to characterize the dose-response relationships and conduct the trials. However, the parametric models are hard to justify in practice, and the misspecification of parametric models can lead to substantially undesirable performances in phase I/II trials. Moreover, it is difficult for the physicians conducting phase I/II trials to clinically interpret the parameters of these complicated models, and such significant learning costs impede the translation of novel statistical designs into practical trial implementation. To solve these issues, we propose a transparent and efficient phase I/II clinical trial design, referred to as the modified isotonic regression-based design (mISO), to identify the optimal biological doses for molecularly targeted agents and immunotherapy. The mISO design makes no parametric model assumptions on the dose-response relationship and yields desirable performances under any clinically meaningful dose-response curves. The concise, clinically interpretable dose-response models and dose-finding algorithm make the proposed designs highly translational from the statistical community to the clinical community. We further extend the mISO design and develop the mISO-B design to handle the delayed outcomes. Our comprehensive simulation studies show that the mISO and mISO-B designs are highly efficient in optimal biological dose selection and patients allocation and outperform many existing phase I/II clinical trial designs. We also provide a trial example to illustrate the practical implementation of the proposed designs. The software for simulation and trial implementation are available for free download.
Collapse
Affiliation(s)
- Yingjie Qiu
- Department of Biostatistics and Health Data Science, Indiana University, USA
| | - Yi Zhao
- Department of Biostatistics and Health Data Science, Indiana University, USA
| | - Hao Liu
- Department of Biostatistics and Epidemiology, Cancer Institute of New Jersey, Rutgers University, USA
| | - Sha Cao
- Department of Biostatistics and Health Data Science, Indiana University, USA; Center of Computational Biology and Bioinformatics, Indiana University, USA
| | - Chi Zhang
- Center of Computational Biology and Bioinformatics, Indiana University, USA; Department of Medical and Molecular Genetics, Indiana University, USA
| | - Yong Zang
- Department of Biostatistics and Health Data Science, Indiana University, USA; Center of Computational Biology and Bioinformatics, Indiana University, USA.
| |
Collapse
|
3
|
Park Y. Interval design to identify the optimal biological dose for immunotherapy. Contemp Clin Trials Commun 2022; 30:101005. [PMID: 36186542 PMCID: PMC9520219 DOI: 10.1016/j.conctc.2022.101005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 07/31/2022] [Accepted: 09/16/2022] [Indexed: 11/04/2022] Open
Abstract
Immunotherapeutics have revolutionized the treatment of metastatic cancers and are expected to play an increasingly prominent role in the treatment of cancer patients. Recent advances in checkpoint inhibition show promising early results in a number of malignancies, and several treatments have been approved for use. However, the immunotherapeutic agents have been shown to have different mechanisms of antitumor activity from cytotoxic agents, and many limitations and challenges encountered in the traditional paradigm were recently pointed out for immunotherapy. I propose a desirability-based method to determine the optimal biological dose of immunotherapeutics by effectively using toxicity, immune response, and tumor response. Moreover, a new dose allocation algorithm of interval designs is proposed to incorporate immune response in addition to toxicity and tumor response. Simulation studies show that the proposed design has desirable operating characteristics compared to existing dose-finding designs. It also inherits the strengths of interval designs for dose-finding trials, yielding good performance with ease of implementation.
Collapse
Affiliation(s)
- Yeonhee Park
- Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, United States of America
| |
Collapse
|
4
|
Guo B, Zang Y. A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy. Stat Methods Med Res 2022; 31:1104-1119. [PMID: 35191780 PMCID: PMC9305985 DOI: 10.1177/09622802221080753] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Immunotherapy is an innovative treatment that enlists the patient's immune system to battle tumors. The optimal dose for treating patients with an immunotherapeutic agent may differ according to their biomarker status. In this article, we propose a biomarker-based phase I/II dose-finding design for identifying subgroup-specific optimal dose for immunotherapy (BSOI) that jointly models the immune response, toxicity, and efficacy outcomes. We propose parsimonious yet flexible models to borrow information across different types of outcomes and subgroups. We quantify the desirability of the dose using a utility function and adopt a two-stage dose-finding algorithm to find the optimal dose for each subgroup. Simulation studies show that the BSOI design has desirable operating characteristics in selecting the subgroup-specific optimal doses and allocating patients to those optimal doses, and outperforms conventional designs.
Collapse
Affiliation(s)
- Beibei Guo
- Department of Experimental Statistics, 5779Louisiana State University, Baton Rouge, USA
| | - Yong Zang
- Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, USA
- Center for Computational Biology and Bioinformatics, Indiana University, Indianapolis, USA
| |
Collapse
|
5
|
Guo B, Zang Y. BIPSE: A biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint. Stat Med 2022; 41:1205-1224. [PMID: 34821409 PMCID: PMC9335906 DOI: 10.1002/sim.9265] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 09/30/2021] [Accepted: 11/03/2021] [Indexed: 12/19/2022]
Abstract
A Bayesian biomarker-based phase I/II design (BIPSE) is presented for immunotherapy trials with a progression-free survival (PFS) endpoint. The objective is to identify the subgroup-specific optimal dose, defined as the dose with the best risk-benefit tradeoff in each biomarker subgroup. We jointly model the immune response, toxicity outcome, and PFS with information borrowing across subgroups. A plateau model is used to describe the marginal distribution of the immune response. Conditional on the immune response, we model toxicity using probit regression and model PFS using the mixture cure rate model. During the trial, based on the accumulating data, we continuously update model estimates and adaptively randomize patients to doses with high desirability within each subgroup. Simulation studies show that the BIPSE design has desirable operating characteristics in selecting the subgroup-specific optimal doses and allocating patients to those optimal doses, and outperforms conventional designs.
Collapse
Affiliation(s)
- Beibei Guo
- Department of Experimental Statistics, Louisiana State University, Baton Rouge, Louisiana, USA
| | - Yong Zang
- Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, Indiana, USA
- Center for Computational Biology and Bioinformatics, Indiana University, Indianapolis, Indiana, USA
| |
Collapse
|
6
|
Mu R, Xu J, Tang RS, Kopetz S, Yuan Y. A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications. Stat Med 2021; 41:374-389. [PMID: 34730248 DOI: 10.1002/sim.9242] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Revised: 10/10/2021] [Accepted: 10/12/2021] [Indexed: 12/26/2022]
Abstract
There is a growing trend to combine a new targeted or immunotherapy agent with the cancer-specific standard of care to treat different types of cancers. We propose a master-protocol-based, Bayesian phase I/II platform design to co-develop combination (BPCC) therapies in multiple indications. Under the BPCC design, only a single master protocol is needed, and the combined drug is evaluated in different indications in a concurrent or staggered fashion. For each indication, we jointly model dose-toxicity and -efficacy relationships and employ Bayesian hierarchical models to borrow information across them for more efficient indication-specific decision-making. To account for the characteristic of targeted or immunotherapy agents that their efficacy may not monotonically increase with the dose, and often plateau at high doses, we use the utility to quantify the risk-benefit tradeoff of the treatment. At each interim, we update the toxicity and efficacy model, as well as the estimate of the utility, based on the observed data across indications to inform the indication-specific decision of dose escalation and de-escalation and identify the optimal biological dose for each indication. Simulation study shows that the BPCC design has desirable operating characteristics, and that it provides an efficient approach to accelerate the development of combination therapies.
Collapse
Affiliation(s)
- Rongji Mu
- Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Jin Xu
- KLATASDS-MOE, School of Statistics, East China Normal University, Shanghai, China
| | - Rui Sammi Tang
- Department of Biometrics, Servier Pharmaceuticals, Boston, Massachusetts, USA
| | - Scott Kopetz
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Ying Yuan
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
7
|
Biard L, Lee SM, Cheng B. Seamless phase I/II design for novel anticancer agents with competing disease progression. Stat Med 2021; 40:4568-4581. [PMID: 34213022 PMCID: PMC9202313 DOI: 10.1002/sim.9080] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Revised: 03/19/2021] [Accepted: 05/09/2021] [Indexed: 11/08/2022]
Abstract
Molecularly targeted agents and immunotherapies have prolonged administration and complicated toxicity and efficacy profiles requiring longer toxicity observation windows and the inclusion of efficacy information to identify the optimal dose. Methods have been proposed to either jointly model toxicity and efficacy, or for prolonged observation windows. However, it is inappropriate to address these issues individually in the setting of dose-finding because longer toxicity windows increase the risk of patients experiencing disease progression and discontinuing the trial, with progression defining a competing event to toxicity, and progression-free survival being a commonly used efficacy endpoint. No method has been proposed to address this issue in a competing risk framework. We propose a seamless phase I/II design, namely the competing risks continual reassessment method (CR-CRM). Given an observation window, the objective is to recommend doses that minimize the progression probability, among a set of tolerable doses in terms of toxicity risk. In toxicity-centered stage of the design, doses are assigned based on toxicity alone, and in optimization stage of the design, doses are assigned integrating both toxicity and progression information. Design operating characteristics were examined in a simulation study compared with benchmark performances, including sensitivity to time-varying hazards and correlated events. The method performs well in selecting doses with acceptable toxicity risk and minimum progression risk across a wide range of scenarios.
Collapse
Affiliation(s)
- Lucie Biard
- Department of Biostatistics, Columbia University Mailman School of Public Health, New York, USA
- Université de Paris, AP-HP, Hôpital Saint Louis, DMU PRISME, INSERM U1153 Team ECSTRRA, Paris, France
| | - Shing M. Lee
- Department of Biostatistics, Columbia University Mailman School of Public Health, New York, USA
| | - Bin Cheng
- Department of Biostatistics, Columbia University Mailman School of Public Health, New York, USA
| |
Collapse
|
8
|
Mu R, Xu G, Liu G, Pan H. A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials. Contemp Clin Trials 2021; 108:106504. [PMID: 34303862 DOI: 10.1016/j.cct.2021.106504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 06/02/2021] [Accepted: 07/08/2021] [Indexed: 12/01/2022]
Abstract
Conventional phase I designs for finding a phase II recommended dose (P2RD) based on toxicity alone is problematic because the maximum tolerated dose (MTD) is not necessarily the optimal dose. Instead, recently attention has been given to find the minimum effective dose (MinED) - defined as the lowest effective dose. Traditional paradigms for the MinED studies are conducted as dose-ranging or dose-response trials which involve several doses and randomize patients among doses to find the MinED. An alternative approach for the MinED study is the so-called MinED-based dose-finding study, in which instead of conducting hypothesis testings and without power analysis, this kind of trial conduct dose escalation/de-escalation to target a pre-set MinED target. In this study, we propose a new Bayesian two-stage adaptive design schema based on framework of the interval-based phase I method. The proposed method is model-free without curve pre-specifications, which is suitable for various dose-efficacy relationships. The proposed method shows desirable theoretical finite property of semi-coherence and large sample property of consistency. A random scenario generative algorithm for the MinED has also been proposed for extensive simulation studies, which demonstrated desirable performances of the proposed method. An R package "MinEDfind" and a Shiny app have been developed for implementing the method.
Collapse
Affiliation(s)
- Rongji Mu
- Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - Guoying Xu
- Jiangsu Hengrui Medicine Co., Ltd, Shanghai 201203, China
| | - Guanfu Liu
- School of Statistics and Information, Shanghai University of International Business and Economics, Shanghai 201620, China
| | - Haitao Pan
- Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
| |
Collapse
|
9
|
Guo B, Garrett‐Mayer E, Liu S. A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent. J R Stat Soc Ser C Appl Stat 2021. [DOI: 10.1111/rssc.12508] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Beibei Guo
- Department of Experimental Statistics Louisiana State University Baton Rouge LA70803USA
| | - Elizabeth Garrett‐Mayer
- Center for Research and Analytics (CENTRA) American Society of Clinical Oncology Alexandria VA22314USA
| | - Suyu Liu
- Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas77030USA
| |
Collapse
|
10
|
Andrillon A, Chevret S, Lee SM, Biard L. Dose-finding design and benchmark for a right censored endpoint. J Biopharm Stat 2020; 30:948-963. [DOI: 10.1080/10543406.2020.1821702] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Anaïs Andrillon
- INSERM U1153 Team ECSTRRA, Université De Paris, Paris, France
| | - Sylvie Chevret
- INSERM U1153 Team ECSTRRA, Université De Paris, Paris, France
| | - Shing M Lee
- Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA
| | - Lucie Biard
- INSERM U1153 Team ECSTRRA, Université De Paris, Paris, France
| |
Collapse
|
11
|
Mu R, Pan H, Xu G. A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trials. Stat Med 2020; 40:382-402. [PMID: 33094528 DOI: 10.1002/sim.8780] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Revised: 08/23/2020] [Accepted: 10/01/2020] [Indexed: 11/11/2022]
Abstract
Immunotherapy is the most promising new cancer treatment for various pediatric tumors and has resulted in an unprecedented surge in the number of novel immunotherapeutic treatments that need to be evaluated in clinical trials. Most phase I/II trial designs have been developed for evaluating only one candidate treatment at a time, and are thus not optimal for this task. To address these issues, we propose a Bayesian phase I/II platform trial design, which accounts for the unique features of immunotherapy, thereby allowing investigators to continuously screen a large number of immunotherapeutic treatments in an efficient and seamless manner. The elicited numerical utility is adopted to account for the risk-benefit trade-off and to quantify the desirability of the dose. During the trial, inefficacious or overly toxic treatments are adaptively dropped from the trial and the promising treatments are graduated from the trial to the next stage of development. Once an experimental treatment is dropped or graduated, the next available new treatment can be immediately added and tested. Extensive simulation studies have demonstrated the desirable operating characteristics of the proposed design.
Collapse
Affiliation(s)
- Rongji Mu
- KLATASDS-MOE, School of Statistics, East China Normal University, Shanghai, China
| | - Haitao Pan
- Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Guoying Xu
- Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| |
Collapse
|